Enbrel is a biologic approved for the treatment of moderate-to-severe psoriasis and psoriatic arthritis.

What is Enbrel?

The drug Enbrel (also known by its generic name etanercept) is a TNF-alpha inhibitor that was approved for people with psoriatic arthritis in January 2002 and for moderate-to-severe psoriasis in April 2004. In November 2016, the psoriasis indication was extended to include pediatric patients ages 4 years and older. In 2023, Enbrel was approved for the treatment of active juvenile psoriatic arthritis (JPsA) in pediatric patients 2 years of age and older. It is also approved for treating rheumatoid arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis.

Enbrel is given by injection under the skin once a week for patients with psoriatic arthritis. For adults with moderate-to-severe psoriasis, Enbrel is administered twice weekly by injections under the skin for 3 months, and then a maintenance dose once per week. Enbrel is administered weekly in pediatric patients with moderate-to-severe psoriasis.

To learn more, please visit the Enbrel website.

Biosimilars for Enbrel

biosimilar is a medication that is highly similar to an existing FDA-approved biologic medicine (aka reference product). Biosimilars have the same strength, dosage, potential benefits, and side effects as the reference product and are administered the same way. Biosimilars still must be FDA-approved.

A teen smiles for a camera while the doctor sands behind her.

Enbrel Approved for Pediatric Psoriasis

FDA’s decision is the first approval of a biologic for use in pediatric psoriasis.

Learn more
Illustrated graphic of people around a rocket ship and computer.

Advance Online

Get the latest news on new treatment options from NPF.

Stay up to date

Learn More About Your Treatment Options

The Patient Navigation Center is here to provide personalized information about your psoriasis and psoriatic arthritis treatment.

Contact a Patient Navigator today

Stay in the Know

Expert tips, can’t-miss events, and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorCommunity Health Charities logo

Copyright © 1996-2023 National Psoriasis Foundation/USA

Duplication, rebroadcast, republication, or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).

NPF does not endorse or accept any responsibility for the content of external websites.

NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.